Retatrutide
Also known as: Triple agonist (GIP/GLP-1/glucagon)
Triple GIP, GLP-1, and Glucagon Receptor Agonist
COMPOUND CLASS
Investigational triple incretin receptor peptide
PRIMARY PATHWAY
GIP, GLP-1, and glucagon receptor signaling
PRIMARY AREAS OF RESEARCH
Energy expenditure, appetite regulation, metabolic markers
RESEARCH STATUS
Investigational — early to mid-stage human clinical trials
EVIDENCE LEVEL
Early
OTHER NAMES
Triple agonist (GIP/GLP-1/glucagon)
What Is Retatrutide?
Retatrutide is an experimental peptide built to switch on three different cell receptors that all play a role in how the body handles energy. Two of them, GIP and GLP-1, respond to hormones released by the gut after eating. The third responds to glucagon, a hormone from the pancreas that tells the liver to release stored energy.
Combining three signals in a single molecule is sometimes called 'unimolecular polypharmacy' — one compound doing the job of several. Researchers study it partly to learn what happens when these pathways are activated together rather than one at a time.
- What it is
- An investigational peptide designed to activate three metabolic receptors at once.
- Category
- Metabolic research compound — triple GIP, GLP-1, and glucagon receptor agonist.
- Main system involved
- Gut hormone signaling plus liver energy metabolism.
- Research interest
- Body-weight physiology, energy expenditure, glucose handling, and liver fat.
- Research status
- Investigational; phase 2 human trial results published, larger long-term studies ongoing.
Why Are Researchers Interested?
Three pathways, one molecule
It is a useful research model for understanding how incretin signaling and glucagon signaling interact.
Energy expenditure, not just intake
Glucagon signaling is associated with the body burning energy, so researchers are investigating whether this adds something beyond appetite reduction.
Liver metabolism
Early trial data has examined liver fat content. This is promising but still early-stage evidence.
Published human trial results
Phase 2 results in humans have been published, which places it further along than purely preclinical compounds — but it is not a finished story.
How It Works
Think of the body's energy system as having an 'intake' side and a 'burn' side. GLP-1 and GIP signaling mostly influence the intake side: insulin response, digestion speed, and feeling full. Glucagon signaling leans toward the burn side, prompting the liver to mobilize and process stored fuel.
Retatrutide is being studied because it touches both sides at once. Researchers want to know whether the combination behaves like the sum of its parts or produces a different metabolic pattern altogether.
Current Areas of Research
Multi-receptor biology
How much of each receptor signal is optimal, and how the three interact.
Energy expenditure and weight
Whether energy burn increases alongside appetite changes in controlled studies.
Liver fat and lipids
Early measurements of hepatic fat and how the liver handles fats.
Glucose and insulin sensitivity
Blood sugar responses after meals and markers of how well the body responds to insulin.
Longer-term biomarkers
Cardiometabolic markers tracked over time in supervised research settings.
What Does the Evidence Actually Say?
Early — published phase 1 and phase 2 human trials exist, but the compound is not approved and large long-term outcome trials are still in progress.
Side Effects & Safety Research
Documented in research
- Published trials most commonly report gastrointestinal effects, similar in character to other incretin compounds.
- Heart-rate changes have been reported and tracked as a study endpoint.
Possible or theoretical
- Adding glucagon-receptor activity may influence energy expenditure and hepatic metabolism in ways still being characterized.
Where evidence is insufficient
- No long-term human safety data is available; the compound remains investigational.
What We Don't Know Yet
- Retatrutide remains investigational; large long-term human trials are still in progress.
- Because glucagon signaling can raise blood sugar in some contexts, balancing the three receptor activities is an unresolved scientific question.
- Durability of effects and what happens after discontinuation have not been established.
- Safety data is far less mature than for compounds with years of clinical use.
Frequently Asked Questions
Research References
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022.
- Tschöp MH et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metabolism, 2016.
Key Takeaway
Retatrutide is an investigational triple-receptor peptide that combines gut hormone signaling with glucagon signaling in a single molecule. Researchers are studying it to understand how appetite, blood sugar, energy expenditure, and liver metabolism respond when these pathways are activated together. Published phase 2 human data exists, but the compound remains experimental and long-term evidence is still being gathered.
Related Research
This information is provided for educational purposes only and summarizes current areas of scientific research. It is not medical advice, a treatment recommendation, or an instruction for personal use. Research findings may be preliminary, limited, or subject to change as new evidence becomes available.